Abstract:Abstract Objective Alzheimer's disease (AD) is a degenerative disease of central nervous system with unclear pathogenesis, accounting for 60% - 70% of dementia cases. It is necessary to study the pathogenesis and therapeutic prospect of AD. LncRNAs have been found to play an important role in the development of AD. This study aims to explore the role of differentially expressed lncRNAs in AD patients' serum in the pathogenesis of AD. Methods In this study, serum microarray analysis was performed in AD patients and healthy controls to establish lncRNAs and mRNA expression profiles. The biological processes and key pathways were identified by GO analysis and KEGG pathway analysis. A protein-protein interaction network was analyzed and constructed by using String database. SH-SY5Y cells were treated with Aβ 1-42 to establish AD cell model. The expression of RP11-59J16.2 and MCM2 was detected by qRT-PCR. The mRNA binding sites and target genes of RP11-59J16.2 were predicted by bioinformatics analysis. Dual luciferase reporter gene analysis verified the targeting effect of RP11-59J16.2 on MCM2. Inhibition of RP11-59J16.2 or overexpression of MCM2, CCK-8 and flow cytometry were used to detect cell viability and apoptosis and Western Blot was used to detect the expression of p-Tau. Results Differential expression of lncRNAs and mRNAs was screened by microarray data, and high expression of RP11-59J16.2 and low expression of MCM2 were detected in serum of AD patients. GO analysis and KEGG pathway analysis revealed that G 1 /S transition of mitotic cell cycle may be involved in the development of AD. The mRNA binding sites and target genes of RP11-59J16.2 were predicted by bioinformatics analysis. Dual luciferase reporter gene analysis, qRT-PCR and Western Blot were used to verify the targeted regulation of RP11-59J16.2 on MCM2. The expression of RP11-59J16.2 was increased and that of MCM2 was decreased in SH-SY5Y cells treated with Aβ1-42. CCK-8 assay and Annexin V FITC/PI apoptosis assay kit results showed that RP11-59J16.2 could reduce cell viability, aggravate apoptosis and increase Tau phosphorylation in AD cell model by inhibiting MCM2. Conclusion Through gene microarray and bioinformatics analysis, high differentially expressed lncRNAs RP11-59J16.2 and low expressed mRNA MCM2 in AD patients were screened. By using bioinformatics prediction and dual luciferase reporter gene analysis, it was confirmed that RP11-59J16.2 could target MCM2 regulation. SH-SY5Y cells were treated with Aβ1-42 to construct AD cell model. Overexpression or inhibition of RP11-59J16.2 or MCM2, we found that RP11-59J16.2 could promote neuronal apoptosis and increase Tau phosphorylation by regulating MCM2 in vitro. Thus, RP11-59J16.2 might be a potential target molecule for the prediction, diagnosis and treatment of AD.

Expression of ITPR2 regulated by lncRNA-NONMMUT020270.2 in LPS-stimulated HT22 cells

LncRNA RP11-59J16.2 aggravates apoptosis and increases tau phosphorylation by targeting MCM2 in AD

Immunoproteasome Subunit Low Molecular Mass Peptide 2 (LMP2) Deficiency Ameliorates LPS/Aβ1-42-Induced Neuroinflammation

RNA interference silencing P2X7 receptor restrained inflammatory factors released from the microglia

[Effects of RNA Interference Targeting P2X7 Receptor on Microglial Phagocytosis of Amyloid-Β Protein].

LncRNA RP11-59J16.2 Aggravates Apoptosis and Increases Tau Phosphorylation via Inhibiting MCM2 On The AD SH-SY5Y Cell Model Induced By Aβ.

Deficiency of NLRP3 Protects Cerebral Pericytes and Attenuates Alzheimer’s Pathology in Tau-Transgenic Mice

TRPM2 channel regulates cytokines production in astrocytes and aggravates brain disorder during lipopolysaccharide-induced endotoxin sepsis.

Silencing of LRP1 Exacerbates Inflammatory Response Via TLR4/NF-κB/MAPKs Signaling Pathways in APP/PS1 Transgenic Mice

Expression of tiRNA and tRF in APP/PS1 transgenic mice and the change of related proteins expression

Silencing I-2(Pp2a) Rescues Tau Pathologies And Memory Deficits Through Rescuing Pp2a And Inhibiting Gsk-3 Beta Signaling In Human Tau Transgenic Mice

Abnormal Expression of Long Noncoding RNAs in Primary Immune Thrombocytopenia: A Microarray Related Study.

Suppression of lncRNA-ATB prevents amyloid-β-induced neurotoxicity in PC12 cells via regulating miR-200/ZNF217 axis

Silencing [Formula: see text] Rescues Tau Pathologies and Memory Deficits through Rescuing PP2A and Inhibiting GSK-3β Signaling in Human Tau Transgenic Mice.

Silencing PP2A Inhibitor by Lenti-Shrna Interference Ameliorates Neuropathologies and Memory Deficits in Tg2576 Mice.

LRP1 knockdown aggravates A<sub>1-42</sub>-stimulated microglial and astrocytic neuroinflammatory responses by modulating TLR4/NF-B/MAPKs signaling pathways

LRP1 knockdown aggravates Aβ 1-42 -stimulated microglial and astrocytic neuroinflammatory responses by modulating TLR4/NF-κB/MAPKs signaling pathways.

LRP1 knockdown aggravates Aβ1-42-stimulated microglial and astrocytic neuroinflammatory responses by modulating TLR4/NF-κB/MAPKs signaling pathways

Downregulating expression of OPTN elevates neuroinflammation via AIM2 inflammasome- and RIPK1-activating mechanisms in APP/PS1 transgenic mice

Interaction Between TRPML1 and P62 in Regulating Autophagosome-Lysosome Fusion and Impeding Neuroaxonal Dystrophy in Alzheimer’s Disease

RETRACTED: Long Non-Coding RNA PVT1 Promote LPS-induced Septic Acute Kidney Injury by Regulating TNFα and JNK/NF-κB Pathways in HK-2 Cells